US imposes 100% tariff on imported patented pharmaceuticals, impacting Australian exporters like CSL
Consensus Summary
Donald Trump imposed a 100% tariff on patented pharmaceuticals imported to the US, targeting Australia’s largest exporters like CSL, which supplies a significant portion of the $1.3 billion annual trade. The move, enacted under Section 232 of the Trade Expansion Act, excludes generic drugs and includes exemptions for plasma-derived therapies if they meet US health needs or come from countries with trade deals. CSL, which has major US manufacturing operations, is expected to secure exemptions due to its domestic production, though smaller exporters face uncertainty. The tariff reduces to 20% for companies relocating production to the US and to zero if the US achieves 'most favoured nation' drug pricing status. Countries like Japan, the EU, and the UK received lower tariff rates, reflecting negotiated trade deals. The Australian government, led by Health Minister Mark Butler, has ruled out changes to the Pharmaceutical Benefits Scheme (PBS) and is confident CSL will be exempted, though opposition leader Angus Taylor has pledged to push for broader exemptions. The tariff is part of Trump’s broader push to reshoring pharmaceutical manufacturing, citing national security concerns, and comes amid ongoing US frustration with lower drug prices in countries like Australia. While CSL has invested heavily in US production to mitigate risks, smaller exporters and the broader industry face potential disruptions, with some warning of reduced new medicine launches due to US pricing pressures.
✓ Verified by 2+ sources
Key details reported by multiple sources:
- Donald Trump signed an executive order on 2025-06-26 (Thursday) imposing a 100% tariff on patented drugs imported to the US under Section 232 of the Trade Expansion Act, unaffected by the February 2025 Supreme Court ruling on 'Liberation Day' tariffs.
- Australia exported $US1.32 billion (2025 data) or $US1.3 billion (2024 data) worth of pharmaceuticals to the US annually, with CSL accounting for the majority of these exports.
- CSL has US manufacturing facilities in Illinois (Kankakee) and North Carolina, with a $US1.5 billion ($2.17 billion AUD) expansion announced in 2024, set to complete by 2031, and a $US2.2 billion expansion under construction as of March 2025.
- The tariff applies to patented drugs only, excluding generic medicines, and includes exemptions for plasma-derived therapies if they meet an urgent US health need or come from countries with a trade deal with the US.
- Companies moving production to the US can reduce tariffs to 20%, and to zero if the US achieves 'most favoured nation' status on drug pricing from the exporting country.
- Japan, the EU, South Korea, Switzerland, and Liechtenstein received 15% tariff rates, while the UK secured a 10% rate (with potential for zero).
- Large pharmaceutical companies have 120 days (until October 2025) to announce re-shoring plans to reduce tariffs to 20%, while smaller companies have 180 days (until December 2025).
- Health Minister Mark Butler stated Australia would not negotiate changes to the Pharmaceutical Benefits Scheme (PBS) and remains 'pretty confident' CSL will be exempted due to its US manufacturing operations.
- Opposition Leader Angus Taylor expressed concern and pledged to work with the government to overturn the tariffs or secure exemptions for Australian exporters.
Points of Difference
Details reported by only one source:
- The tariff announcement was timed to mark one year since Trump’s 'Liberation Day' tariffs (February 2025).
- The executive order includes adjustments to steel tariffs: zero for products with less than 15% steel content, 25% for products exceeding 15% steel content.
- The White House official mentioned 'fool the tariff process' attempts to reduce product valuation and cited AstraZeneca as having struck specific deals with the White House.
- Medicines Australia stated that 'most favoured nation' rules are hampering imports to Australia, with new medicines launches being scrutinized due to low Australian prices.
- The tariff is invoked under national security powers, with Trump stating it addresses 'threatened impairment of the national security' from pharmaceutical imports.
- The order explicitly mentions 'pharmaceutical ingredients' as part of the tariff scope.
- The article repeats SMH details verbatim, with no additional unique information.
- A senior administration official stated that 'too many drugs driven by research and development in the US are now produced abroad,' making the US 'beholden to these other countries.'
- Trump previously suggested the tariff could be as high as 200%, and the tariff was expected to take effect from October 2024 but was delayed.
- CSL stated in September 2024 it did 'not expect any material impact' from the tariff's implementation.
- Communications Minister Anika Wells stated the Australian PBS is 'world leading' and 'not for sale,' emphasizing the quality of Australian pharmaceuticals.
- The Guardian noted the tariff decision is part of broader US efforts to force changes to overseas pricing systems like Australia's PBS.
Contradictions
Conflicting information between sources:
- ABC states Trump previously suggested the tariff could be as high as 200%, while all other sources report the final tariff is 100%.
- SMH and ABC mention a 2024 expectation that the tariff would take effect from October 2024, but the actual implementation date is June 2025 according to all sources.
- The Guardian reports Australia exports $2 billion worth of drugs to the US annually, while other sources report $US1.32 billion or $US1.3 billion.
- SMH and ABC mention a 15% steel content threshold for adjusted tariffs, but only SMH explicitly states the tariff would be zero for products with less than 15% steel and 25% for those exceeding it.
- The Guardian states CSL's plasma therapies are 'made entirely from US-sourced plasma,' while other sources do not specify the origin of the plasma used in CSL's products.
Source Articles
Trump slaps huge tariff on medicines
US President Donald Trump has followed through on another tariff threat, putting a 100 per cent levy on a major Australian export....
Trump imposes 100 per cent tariff on Australian drugs – but with caveats
Australia’s largest biotech firm, CSL, could be exempt from the new tariffs, which will not apply to therapies derived from blood plasma in certain circumstances....
Breaking: Trump puts 100pc tariff on some pharmaceuticals
The US president's latest order shows he remains committed to his aggressive tariff regime despite February's Supreme Court ruling that invalidated his centrepiece "liberation day" tariffs....
Australia says it won’t raise drug prices after Trump’s 100% tariff on pharmaceuticals imported into US
Health minister Mark Butler says federal government is ‘not negotiating’ when it comes to removing price protections on common medications Get our breaking news email , free app or daily news podcast ...
What Trump's 100 per cent pharmaceutical tariff means for Australia
Australia exported nearly two billion dollars worth of pharmaceuticals to the US last year....
Trump imposes 100 per cent tariff on Australian drugs – but with caveats
Australia’s largest biotech firm, CSL, could be exempt from the new tariffs, which will not apply to therapies derived from blood plasma in certain circumstances....